CatSci Ltd, an award-winning innovation partner for medicines development, will be attending TIDES USA, taking place on 14th – 17th May 2024 in Boston, MA. TIDES USA will bring together industry experts in the oligonucleotide therapeutics space, ranging from discovery, preclinical, and clinical development through CMC, manufacturing and commercialisation.
Attending TIDES will be:
- Dr Nigel Richardson, our Director of New Modalities
- Carlos R. Côté, our Senior Business Development Manager in Boston
Nigel and Carlos are looking forward to networking with like-minded industry professionals, scientists, and researchers in the oligonucleotides space. They will offer their own insight around these complex molecules, as well as discuss CatSci’s extensive expertise in this area.
CatSci offers scalable manufacturing for all classes of therapeutic oligonucleotides, including siRNA, ASO, Gapmers, and sgRNA. We can synthesise oligonucleotides up to a 30g scale, including complex conjugates like GalNAc ligands, and also have extensive knowledge for supporting IND and NDA enabling packages. Whether it is complex sequencing and structural characterisation of novel 100mers, method development and validation for commercial manufacturing, or batch release and impurity analysis of starting materials, we have the expertise to deliver your project.
To book a meeting with Nigel and Carlos at TIDES USA to learn more about how CatSci can support your next RNA therapeutics project, get in touch with us here.
